Johnson & Johnson seeks FDA approval for subcutaneous induction regimen of Tremfya in ulcerative colitis. The move aims to provide a more convenient treatment option for patients. The drug is already approved for other indications and may help offset potential sales decline of Stelara in the IBD space.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing